Summary
By illegally approving chemical abortion drugs, the U.S. Food and Drug Administration failed to abide by its legal obligations to protect the health, safety, and welfare of girls and women. The FDA never studied the safety of the drugs under the labeled conditions of use, ignored the potential impacts of the hormone-blocking regimen on the developing bodies of adolescent girls, disregarded the substantial evidence that chemical abortion drugs cause more complications than surgical abortions, and eliminated necessary safeguards for pregnant girls and women who undergo this dangerous drug regimen.
Related Articles
Press Releases
-
ImageAugust 16th, 2023FDA must restore vital safeguards for chemical abortion drugs, 5th Circuit rules
-
ImageMay 16th, 2023Unlawful FDA approval of chemical abortion drugs before 5th Circuit
-
ImageApril 21st, 2023Lawsuit challenging illegal approval of abortion drugs continues
-
ImageApril 18th, 2023Doctors urge Supreme Court to reject FDA's fight to put women at risk
-
ImageApril 14th, 2023Supreme Court issues standard-procedure stay in FDA case
-
ImageApril 14th, 2023ADF: Supreme Court should reject FDA's fight to put women at risk
-
ImageApril 13th, 20235th Circuit ends FDA's illegal mail-order abortion regime
-
ImageApril 12th, 2023ADF to 5th Circuit: FDA must be held accountable for lawlessness
-
ImageApril 10th, 2023FDA's illegal approval of chemical abortion drugs heads to 5th Circuit
-
ImageApril 7th, 2023Court halts FDA's unlawful approval of chemical abortion drugs
-
ImageMarch 15th, 2023ADF to court: Protect women, girls from dangerous chemical abortion drugs
-
ImageFebruary 13th, 2023Groups, officials unite to hold FDA accountable for illegally approving chemical abortion drugs
-
ImageFebruary 10th, 2023Doctors, health care groups push back on FDA attempts to justify illegal approval of chemical abortion drugs
-
ImageNovember 18th, 2022Doctors, health care groups sue FDA for approving dangerous chemical abortion drugs
Case Documents
-
More than 20 years ago, the FDA approved the use of a two-drug regimen for abortion. Both drugs, known as mifepristone and misoprostol, can cause serious complications for women and girls who take them.
The FDA ignored these risks and failed to properly research the potential harms of the drugs before they approved them. Since then, the FDA has removed safeguards that were put in place to protect women and girls seeking these dangerous drugs.
Alliance Defending Freedom’s clients have been challenging the FDA’s approval of these drugs since the beginning, but the FDA has not heeded the concerns. It sat on one petition filed by our clients for 14 years before ultimately denying it. Since the FDA continues to recklessly push dangerous abortion drugs without properly researching and explaining the complications they cause, ADF has filed this lawsuit on behalf of four doctors and four medical associations.
-
Yes. If the drug manufacturer’s own information is to be believed, between 100,000 (2%) and 350,000 (7%) of mifepristone users have had unsuccessful chemical abortions and required surgical intervention. The FDA’s currently approved label for mifepristone also states that between 2.9-4.6% of women will end up in an emergency room.
Women have faced severe bleeding, life-threatening infections, and the inability to give birth to children in the future as a result of these drugs. Women who face these complications can require emergency medical treatment, surgeries, blood transfusions, or hysterectomies to treat them.
-
The FDA first approved chemical abortion drugs in 2000. Former President Bill Clinton and his administration began pressuring French pharmaceutical company Roussel Uclaf to bring mifepristone, the first drug in the two-drug regimen, to the United States between 1993 and 1994. The company “donated” the U.S. patent for the drug to The Population Council, an organization that was founded to address “world overpopulation.”
The Population Council filed a new drug application with the FDA in 1996, and the FDA gave it priority review. It initially approved the drug, asked for more information, and by 2000, it approved the two-drug abortion regimen of mifepristone and misoprostol for use in the United States with minimal restrictions. Since that time, the FDA has removed the few safeguards that were in place initially.
-
Initially, the FDA required women and girls to attend three in-person doctor’s visits before they could be prescribed chemical abortion drugs. But in 2016, the FDA reduced the number of required in-person visits to one.
In 2021, the FDA claimed it was temporarily removing the in-person requirement due to COVID-19, meaning women and girls could be prescribed chemical abortion drugs via telemedicine and receive them in the mail. It soon made this change permanent, allowing these dangerous drugs to be distributed through the mail without even requiring a single in-person doctor’s visit.
-
No. While proponents of chemical abortion drugs claim they are safe for women and girls, this is false. No abortions are safe, and each one is meant to take an innocent life. But chemical abortion drugs are even more likely than surgical abortions to cause complications for the mother. Research has shown that women and girls who have chemical abortions experience a complication rate that is four times higher than those who have surgical abortions.
Additional Resources
Case Profiles

